Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
tarballmonger...actually just to set the record straight...I read that fast...the 497k is just the prospectus #...not the shares...still means nothing to us...
and good morning to everyone
bull
tarballmonger...I read that ...my understanding is that is just a result of that fund creating their new joint venture and having to list their holdings being removed from the parent co. and put into the new venture...and being required to give that info to their shareholders...I don't see that means anything to us except the fact they own 497k shs of Nuvilex.
And Mariam...as you can see from all the different advice you get from a mb...my advice...don't take advice from a mb...
I can tell you I have a lot of shares and I am not letting one share go to the mm's like people did yesterday..they scooped up every single share that anyone let go of...did you notice the trading...how tight it got with no spread...right after the article came out...not a coincidence....
and because I did a lot of DD on nvlx for my own benefit like I do on all my investments...
the article...it is a big deal...it does mean something to the Phase III Trials and the company and the stock...and if nothing else it validates to the ones like seeking alpo author... what we have been saying about the company and they know it...why do you think they have been going to extremes to get out of their short position so badly...
and since I ran out of messages yesterday...this is all in one...so if I did not answer someone's message to me.. sorry...
bull
I guess too many people that do no DD and do not even know Austrianova is our partner and we also own 14.5 % of Austrianova ...sometimes I just can't take it...this is one of those times...
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
Thu Mar 6, 2014 11:55am EST
bull
What? this is a Technology going into PHASE III TRIALS...for pancreatic cancer...we are in the end trial before approval..so what are you talking about...
bull
Have you guys even read the NEWS minutes ago
do you understand the stock that you own...
this is a MILESTONE....what we longs have been talking about
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
SILVER SPRING, Md., March 6, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its strategic partner, Austrianova, has signed a contract to establish regional Headquarters and a research and development facility at the Thailand Science Park (TSP) near Bangkok, Thailand. These facilities will be used for the encapsulation, using the Cell-in-a-Box™ technology, of live cancer prodrug-activating cells that are part of Nuvilex's pancreatic cancer treatment and that will be used in the Company's late-phase clinical trials involving this deadly disease.
The TSP is a state of the art, newly conceived and built, high-tech campus that already is home to approximately 60 leading international biotech and pharma companies. In addition to housing leading Thai companies, entities from the USA, Germany, Japan and other countries have facilities in the TSP.
Development by Austrianova of a presence at this premier research and development facility in South East Asia is a further step in preparing for the encapsulation of the cancer drug-activating cells that are part of Nuvilex's treatment for advanced pancreatic cancer. Thailand was chosen as the location for the facility because of that country's commitment to making the TSP a life sciences hub for all of Southeast Asia, economic incentives by the Thai government, the well educated workforce that resides in Thailand and because Thailand is a founding member of ASEAN, the Association of Southeast Asian Nations. Nuvilex plans to outsource its live-cell encapsulation needs to Austrianova.
Nuvilex's treatment for advanced pancreatic cancer consists of using low doses of the well-known anticancer agent ifosfamide together with cells capable of converting ifosfamide into its cancer-killing form that have been encapsulated using the proprietary Cell-in-a-Box™ technology. Preparations are currently under way for late-phase clinical trials in pancreatic cancer using this treatment. These future trials are designed to build upon the promising results that were obtained in the previous Phase 1/2 clinical trials (please see http://www.nuvilex.com/pancreatic-cancer).
Kenneth L. Waggoner, Nuvilex's CEO and President commented, "By Austrianova establishing a research and development facility and Headquarters in Thailand means that a significant milestone has been reached along Nuvilex's path towards its late-stage clinical trials in advanced, inoperable pancreatic cancer. This facility is needed in order to establish the cGMP compliant production facility for the encapsulation of cell products for clinical trials. We would like to thank our colleagues at Austrianova for completing this important step in helping Nuvilex to prepare for its future clinical trials in pancreatic cancer. We are looking forward to working closely with Austrianova as those preparations continue."
About TSP
http://www.sciencepark.or.th/index.php/en/about-tsp
bull
Can you say Milestone announced a few minutes ago...
Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
bull
Reuters: Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
just in case you are wondering....
THIS IS YOUR ENTRY POINT
bull
they could of done the R&D in Singapore...but this new park...how awesome....
The TSP is a state of the art, newly conceived and built, high-tech campus that already is home to approximately 60 leading international biotech and pharma companies. In addition to housing leading Thai companies, entities from the USA, Germany, Japan and other countries have facilities in the TSP.
Development by Austrianova of a presence at this premier research and development facility in South East Asia is a further step in preparing for the encapsulation of the cancer drug-activating cells that are part of Nuvilex's treatment for advanced pancreatic cancer. Thailand was chosen as the location for the facility because of that country's commitment to making the TSP a life sciences hub for all of Southeast Asia, economic incentives by the Thai government, the well educated workforce that resides in Thailand and because Thailand is a founding member of ASEAN, the Association of Southeast Asian Nations. Nuvilex plans to outsource its live-cell encapsulation needs to Austrianova.
can you say MILESTONE...
this is what we wait for....
bull
hats off to our partners at Nuvilex...u guys realize they had this info...they could of saved it for the World Asia 2014 ....but didn't...
The 7th annual BioPharma Asia Convention is the leading event for Asia's biopharma industry. Bringing together decision makers and influencers from pharma, biotech, academia, CROs and CMOs it delivers an unparalleled opportunity to convene, network and deliberate.
BioPharma Asia presents itself to key industry stakeholders as an invaluable resource.
bull
Reuters: Nuvilex Partner Austrianova Establishes Regional Headquarters and Research and Development Facility at Thailand Science Park for Cell-in-a-Box(TM) Live-Cell Encapsulation
SILVER SPRING, Md., March 6, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that its strategic partner, Austrianova, has signed a contract to establish regional Headquarters and a research and development facility at the Thailand Science Park (TSP) near Bangkok, Thailand. These facilities will be used for the encapsulation, using the Cell-in-a-Box™ technology, of live cancer prodrug-activating cells that are part of Nuvilex's pancreatic cancer treatment and that will be used in the Company's late-phase clinical trials involving this deadly disease.
The TSP is a state of the art, newly conceived and built, high-tech campus that already is home to approximately 60 leading international biotech and pharma companies. In addition to housing leading Thai companies, entities from the USA, Germany, Japan and other countries have facilities in the TSP.
Development by Austrianova of a presence at this premier research and development facility in South East Asia is a further step in preparing for the encapsulation of the cancer drug-activating cells that are part of Nuvilex's treatment for advanced pancreatic cancer. Thailand was chosen as the location for the facility because of that country's commitment to making the TSP a life sciences hub for all of Southeast Asia, economic incentives by the Thai government, the well educated workforce that resides in Thailand and because Thailand is a founding member of ASEAN, the Association of Southeast Asian Nations. Nuvilex plans to outsource its live-cell encapsulation needs to Austrianova.
Nuvilex's treatment for advanced pancreatic cancer consists of using low doses of the well-known anticancer agent ifosfamide together with cells capable of converting ifosfamide into its cancer-killing form that have been encapsulated using the proprietary Cell-in-a-Box™ technology. Preparations are currently under way for late-phase clinical trials in pancreatic cancer using this treatment. These future trials are designed to build upon the promising results that were obtained in the previous Phase 1/2 clinical trials (please see http://www.nuvilex.com/pancreatic-cancer).
Kenneth L. Waggoner, Nuvilex's CEO and President commented, "By Austrianova establishing a research and development facility and Headquarters in Thailand means that a significant milestone has been reached along Nuvilex's path towards its late-stage clinical trials in advanced, inoperable pancreatic cancer. This facility is needed in order to establish the cGMP compliant production facility for the encapsulation of cell products for clinical trials. We would like to thank our colleagues at Austrianova for completing this important step in helping Nuvilex to prepare for its future clinical trials in pancreatic cancer. We are looking forward to working closely with Austrianova as those preparations continue."
bull
Technical
they took it right down to the previous support....lets see it climb with the trend line...and be patient...no one was complaining with all the green up days...it can't keep going up all the time...pullbacks are healthy for the stock..to rest it....
bull
they are bringing it down...just like the article last week had a purpose..and it was successful...the lower the short interest of the days trading pretty soon the stock will have weeded out most of the short sellers and the weak hands...a stock will then find it's footing where no one wants to sell any lower...hence what is left is strong longs...
this is why I do not trade...I buy and hold because I know what I have and I have patience...
this is not a bad thing...it cleans up the stock...
you see how people panic and end up losing their position to the mm's...they are happy to buy your cheap shares...
bull
they are covering their short position..in 10 days short position has gone from 45% to 25% of the days trading....it will settle down
bull
Date Symbol Name Short Volume Long Volume Total Volume Short%
2014-03-05 NVLX Nuvilex Inc 2595046 7844579 10439625 25
2014-03-04 NVLX Nuvilex Inc 3310139 7341131 10651270 31
2014-03-03 NVLX Nuvilex Inc 8013070 16532966 24546036 33
2014-02-28 NVLX Nuvilex Inc 30792884 58967757 89760641 34
2014-02-27 NVLX Nuvilex Inc 16756808 23959092 40715900 41
2014-02-26 NVLX Nuvilex Inc 11774596 17141243 28915839 41
2014-02-25 NVLX Nuvilex Inc 12624529 25861426 38485955 33
2014-02-24 NVLX Nuvilex Inc 16584475 26941823 43526298 38
2014-02-21 NVLX Nuvilex Inc 13028746 26316838 39345584 33
2014-02-20 NVLX Nuvilex Inc 8836718 14118397 22955115 38
2014-02-19 NVLX Nuvilex Inc 5900485 7330122 13230607 45
this is why they repeat news so it gets into the hands of investors that do not see the small newsletters....
Reuters:Recent Events Effectively De-Risk Nuvilex, Inc.
bull
it seems to be having the same resistance here that it had in the .60's....
not yet
look guys ...quit worrying about the shorts...they will come and go...if you do your DD and know you bought the right stock..you just hold through all the crap..when I do my DD...I don't look for the normal articles out there on every page in front of your face...I search every corner to find a reason not to own the stock...and when I can not find 1 logical reason not to own the stock.... I buy...and I buy heavy...and I hold ....and it works for me...but the foundation is DD...
bull
Legislature 2014: Marijuana for children's seizures approved by Florida House committee
So-called "Charlotte's Web" is non-euphoric drug
Posted: March 5, 2014 - 5:37pm | Updated: March 5, 2014 - 6:14pm
TALLAHASSEE | With just one “no” vote, a Florida House panel signed off on a measure Wednesday that would legalize a strain of non-euphoric marijuana used to treat children wracked by potentially deadly seizures.
House Criminal Justice Chairman Matt Gaetz, the sponsor of the bill known as “Charlotte’s Web,” called the bipartisan support historic because it’s the first time in modern history that the Florida Legislature has advanced any marijuana-related measure.
“That’s because people here in Tallahassee have realized that we can’t just have a bumper-sticker approach to marijuana where you’re either for it or against it. Not all marijuana is created equally. Here, this strain of marijuana can do a lot of good and has a very low likelihood of abuse,” Gaetz, R-Fort Walton Beach, said.
Gaetz’s subcommittee approved the proposal (HB 843) after nearly an hour of testimony from parents and other advocates who believe the strain of marijuana called “Charlotte’s Web” can dramatically reduce seizures in children with a rare form of epilepsy.
Some Republican leaders, including Gaetz’s father, Senate President Don Gaetz, have galvanized support around the Charlotte’s Web measure as an alternative to a proposed constitutional amendment that would allow doctors to write prescriptions for marijuana. Orlando trial lawyer John Morgan, also the boss of Democratic gubernatorial candidate Charlie Crist, is pushing the ballot initiative, which will go before voters in November.
Under the proposal approved Wednesday, strains of marijuana that contain .8 percent or less of tetrahydrocannabinol, the psychoactive component in marijuana, and more than 10 percent of the derivative cannabidiol, or CBD, would be legal, along with the seeds of the plant.
Supporters of the proposal say the amount of THC in Charlotte’s Web, which is not smoked but is ingested as an oil or paste, is not enough to get users high. The proposal also includes $1 million for research on the substance.
Peyton and Holley Moseley’s 10-year-old adopted daughter RayAnn is one of about 125,000 Florida children diagnosed with Dravet Syndrome, a rare form of epilepsy that can cause hundreds of seizures a day and does not respond to other treatments. The couple said they traveled to Colorado, where Charlotte’s Web is manufactured, and met with parents of other children who had responded to the treatment.
“These kids can walk now. These kids can talk now. These kids are saying ‘I love you’ to their parents for the first time,” Peyton Moseley told the panel.
The Florida Sheriffs Association is also backing the measure, which was amended on Wednesday to put the burden on people who are arrested or investigated to prove that the drugs they are holding meet the THC and CBD levels laid out in the bill.
Questioned by his colleagues about enforcement issues, Matt Gaetz said he hoped that state attorneys and other officials would not bring charges against growers and manufacturers or the physicians who distribute the substance to their patients.
But lobbyist Louis Rotundo, who represents a newly formed coalition of businesses and land owners interested in Charlotte’s Web, said the bill as passed poses problems for potential growers and suppliers.
“Frankly, telling me that it’s at the discretion of my state attorney or my sheriff, good men and women that they may be, leaves me a little queasy. I don’t think that you get a loan from a bank on a situation like that,” Rotundo said.
Rep. Gayle Harrell cast the only vote against the measure after asking a series of questions highlighting concerns about a lack of regulation over the substance, especially compared to other drugs.
“If you really want to solve a problem and just not legalize marijuana then you need to do it appropriately,” Harrell, R-Stuart, said.
But Rep. Dave Hood, R-Daytona Beach Shores, argued the bill is a “no-brainer” and implied that it does not go far enough to help cancer survivors like himself whom studies show can benefit from traditional medical marijuana.
“It is absolutely an abomination ... for us to continue to have unreasonable, arbitrary and capricious rules that relate to marijuana,” said Hood, a lawyer.
The measure has two more committee appearances before heading to the House floor. A Senate companion (SB 1030) has not yet had a committee hearing.
bull
older article..but I never saw it...on Trefis....
The Undiscovered Biotech Giant: Nuvilex
April 15th, 2013 by David Gould
Submitted by David Gould as part of our contributors program.
Micro-cap investing can often be very speculative–leaving many investors feeling like they just left the casino. But it doesn’t have to be that way. There are safe micro-cap stocks out there with high-growth potential and minimized downside. Downside has been minimized, because of the irrational discounting mentioned earlier (i.e. investors would rather not go with the risk). Thus, buying a basket of, say, penny stocks would do two things: (1) enable you to profit off of discount rates falling and (2) hedge against the chance that any one of those companies collapses within the portfolios. An even better strategy would be to invest directly in under-recognized companies.
The one gem out there that few investors know about but is likely to provide substantial gains is… Nuvilex (PINK:NVLX). This biotech company has a pancreatic cancer treatment that, in its Phase II clinical trials, doubled the median survival time compared to Lilly’s (LLY) Gemzar, the standard of care as a single agent for advanced pancreatic cancer. In addition, compared to Gemzar, Nuvilex’s pancreatic cancer treatment gave a doubling in the percentage of 1-year survivors. For decades, oncologists have been trying to incrementally improve survival times for many forms of cancer, let alone for pancreatic cancer, one of the deadliest forms of the disease. That a company could come along and introduce a treatment that doubles survival time without soaring in value is unheard of. Nuvilex represents one of the rarest opportunities out there.
Common sense dictates that no company with such a powerful late-stage cancer treatment could maintain a market cap under $100 million for long. Nuvilex is only worth around $30M. This is simply unheard of.
Fortunately, investors are just starting to catch on. The stock price has more than doubled (119%+) over the last 3 months. A Forbes researcher has expressed his bullishness, and the company is now entering the high-profile “Green Rush” that is catching the interests of many investors. Cannabis Science (PINK:CBIS) and Medical Marijuana (PINK:MJNA) have both delivered breakthrough returns. The former is up over 22% while the latter is up over 333%. Marijuana is attracting momentum with investors that points to the growing chorus of “legalize pot” voters for optimism. With over 1,500 dispensaries, 18 states (plus Washington DC) on board, and national legalization efforts, the pot industry is set to go higher and higher.
What exactly is Nuvilex planning on doing in the marijuana space? Ultimately, it is looking to do something very similar to what it did for pancreatic cancer. It is looking to use cannabinoids (the “active” components in marijuana) as the basis on which to build treatments for glioblastoma multiforme, an aggressive brain cancer, as well as for pancreatic cancer.
Cannabinoids, unlike many other commonly-used cancer drugs, appear to be able to cross the “blood-brain” barrier and therefore are good candidates for treating brain cancers. Research has demonstrated that cannabinoids, like “THC” and cannabidiol (CBD), can mitigate tumor growth through an immunological response in addition to other mechanisms, and as a result, a plethora of reports have appeared in prominent scientific publications that testify to the activity of cannabinoids for the treatment of a variety of cancers. Accordingly, the science behind what Nuvilex plans to do is well supported by peer reviewed scientific literature.
Furthermore, Nuvilex’s cell encapsulation technology is revolutionary. The technology has already been used in their pancreatic cancer treatment. If it can be combined with cannabinoids, it may not only be able to improve efficacy of cancer treatments (like the cell encapsulation-based product has done independently) but also improve the quality of life of patients undergoing treatment for some of the most lethal of all cancers. Marijuana is already being prescribed mostly for pain treatment, and has been shown to ameliorate the cachexia, or “wasting’ syndrome associated with many advanced cancers. Therefore, medical marijuana very likely has diverse properties when used in cancer treatments. This provides for significant opportunity with minimal downside.
Finally, I would like to conclude by highlighting how the firm’s COO, Dr. Gerry Crabtree, PhD comes equipped with experience in Big Pharma. He worked for Bristol Myers (BMY) as Project Manager in the development of Taxol, a breakthrough product. He has published north of 80 peer-reviewed articles and coordinated the development of multiple drug candidates. He knows a strong pipeline when he sees it. It is time for the market to start seeing the same thing.
bull
Nice close @ 0.42....perspective: we closed @ 0.438 yesterday..
longs are taking their time to get in the lowest pps...I personaly think we are there..I think we are bottoming...
we are getting ready to hit the trend line tomorrow...GL
there is everyone happy now?..
bull
Nice close @ 0.42.....the shorts want to make you think this is taking a dive....perspective: we closed @ 0.438 yesterday..
longs are taking their time to get in the lowest pps...I personaly think we are there..I think we are bottoming...
we are getting ready to hit the trend line tomorrow...GL
bull
don't let the shorts fool you...we have killed the shorts lately;;
Date Symbol Name Short Volume Long Volume Total Volume Short%
2014-03-04 NVLX Nuvilex Inc 3310139 7341131 10651270 31
2014-03-03 NVLX Nuvilex Inc 8013070 16532966 24546036 33
2014-02-28 NVLX Nuvilex Inc 30792884 58967757 89760641 34
2014-02-27 NVLX Nuvilex Inc 16756808 23959092 40715900 41
2014-02-26 NVLX Nuvilex Inc 11774596 17141243 28915839 41
2014-02-25 NVLX Nuvilex Inc 12624529 25861426 38485955 33
2014-02-24 NVLX Nuvilex Inc 16584475 26941823 43526298 38
2014-02-21 NVLX Nuvilex Inc 13028746 26316838 39345584 33
2014-02-20 NVLX Nuvilex Inc 8836718 14118397 22955115 38
2014-02-19 NVLX Nuvilex Inc 5900485 7330122 13230607 45
bull
iwitness4jc ...that all depends on what the company announces on milestones for phase III trials...just hold and be patient..
and if you want to add... right here would be a good place maybe even before 3:15 today ...just my opinion based on charting the stock
and it has strength ...last time it acted this way was on lower volume than this for 2 days and then the stock took off...low volume ...no one wants to sell ...the lows I have given are holding so far...I like it
bull
it seems like the only thing floundering lately is the comments being used against Nuvilex.....the stock is consolidating nicely in here...just my opinion
bull
the last time we consolidated like this with less volume than this was for 2 days ....right before the climb up....keep this in mind if you are looking for an entry....I think we are preparing for the next leg up...GO LONGS...
bull
I disagree with you styl...they did not buy 100% of SG Austria because they did not need to... and they did it that way because it benefited the shareholders.....they returned all the shares from the original purchase agreement back to the company's treasury...thus not diluting the shareholders with those shs...
bull
are you looking at the same charts I am.....this is beautiful sideways consolidation with the momo's gone....and may I add it is up from Friday's pullback that we are consolidating...
keep
I am thinking 0.425 is the low today...until amateur hour is over about 11 it is hard to tell...
bull
Austrianova Singapore Pte Ltd patents
Recent patent applications which may be related to Austrianova Singapore Pte Ltd. They are listed under Austrianova Singapore Pte Ltd because the company is listed as an Agent/Assignee. Note: Austrianova Singapore Pte Ltd may have other listings under a different name/spelling, and it's possible similarly-named companies could have patents on this list. Also, we're not affiliated with Austrianova Singapore Pte Ltd, we're just tracking patents.
Count Application # Date Austrianova Singapore Pte Ltd patents
1 20140023693 01/23/14 Protection of microbial cells from acidic degradation
note the date
bull
yeah and you can tell as longs we are so worried ...Nuvilex down
a penny....let's put that into perspective...shall we
yesterday UP 0.0225 .... today down 0.0145....hmmmm
bull
this information is out there on Nuvilex's website and on the sec documents....and I know the true longs already know this...there is plenty more...but so many want everyone to do their homework for them...I usually won't ....because I don't like laziness ...but if this will help you new guys to understand a little more it is worth it...please go do some DD...you won't believe the confidence you will gain by doing it....you won't have any more questions and you won't sell a single share of your Nuvilex stock...
Bavarian Nordic (BAVA.CO) holds the patents for Cell-in-Box and Vac-in-a-Box....to which Bio Blue Bird AG (BBB) licensed the rights to them...in the first purchase agreement Nuvilex was to buy the parent co. SG Austria who's Private Limited’s wholly-owned was Bio Blue Bird AG....Nuvilex wanted the worldwide rights that BBB had...but in the Third Addendum to the purchase agreement the terms were changed...
here they are:
Third Addendum to Asset Purchase Agreement
On or about July 10, 2013, with an effective date of June 25, 2013, the Registrant and SG Austria Private Limited (“SG Austria”) notified shareholders that they had executed and completed the majority of tasks necessary to fulfill and complete the Third Addendum (the “Third Addendum”) to the original Asset Purchase Agreement between the companies, dated May 26, 2011. Under the terms of the Third Addendum, the Registrant acquired 100% of the equity interests in Bio Blue Bird AG (BBB) from BBB's parent company SG Austria and, in addition, received a 14.5% equity interest in SG Austria for payments made to date.
The Registrant paid $1.5 million USD in cash to acquire BBB. Funding was accomplished through a private placement sale to accredited investors of 12,000,000 shares of the Company's restricted common stock for $0.125 per share. The original Agreement planned for 100,000,000 shares of the common stock of the Registrant (the “Escrow Shares”) to be issued in connection with a transaction to acquire all assets and stock (the equity interests) of SG Austria. The Third Addendum instead provides that the Registrant would acquire 100% of the equity interests in BBB, 14.5% of the equity interest in SG Austria, and Escrow Shares would be returned to the Registrant's treasury.
BBB is now a debt-free wholly-owned subsidiary of the Registrant and provides exclusive worldwide licenses for the use of encapsulation for oncology, through patents licensed by BBB from Bavarian Nordic (BAVA.CO, Listed on NASDAQ OMX Copenhagen), a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases. This licensing enables the Registrant to carry out any form of living-cell encapsulation-based cancer treatment and encapsulation of virus expressing cells for treating diseases.
so now nuvilex owning 100% of BBB gave us the worldwide rights...
and we did not have to buy 100% of the parent co..SG Austria...for all those shares so they got returned to us and in the process ended up owning 14.5% ( BBB's % )of the SG Austria...
SG Austria Pte Ltd (operating: Austrianova Singapore Pte Ltd.) is who is doing all the R&D...hence why we are working with them to further Cell-in-a-Box....
SG Austria (operating under Austrianova Singapore Pte Ltd), was established in 2007; whilst based in Singapore’s top research biotech hub, Biopolis, it has a global footprint. In addition to offering Cell-in-a-Box and Bac-in-a-Box business to business, SG Austria is also developing it's own oncology product which has already been in multiple, sucessful clinical trials. SG Austria also provides services around the GMP manufacturing of encapsulated cell products.
so we also bought the licensing from them to use the trademark:
Licensing Agreement
On July 10, 2013, with an effective date of June 25, 2013, the Registrant negotiated and obtained a Licensing Agreement, to further expand the interests of the Company which is entirely unrelated to the Third Addendum and purchase of Bio Blue Bird AG described above.
This Licensing Agreement with Austrianova Singapore Pte Ltd. (“ASPL” or “ANS”), grants to the Registrant an exclusive worldwide license to use the Cell-In-A-Box® trademark and its associated technology.
Nuvilex Inc said that BBB has exclusive universal licenses for the pancreatic cancer treatment based on live-cell encapsulation. These licenses offer rights to use the live-cell encapsulation for development of treatments for cancer types based on any cell type encapsulated.
The company will be able to use technology for the pancreatic cancer trials. The purchase price paid is $1.5 million.
Jan. 30, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has received its share issuance from SGAustria Pte. Ltd. (Austrianova), who owns Austrianova Singapore Pte. Ltd. (Austrianova Singapore), that equates to a 14.5% equity interest in Austrianova.
The issuance of shares by Austrianova fulfils an obligation by Austrianova to Nuvilex that was part of the Asset Purchase Agreement between both companies pertaining to the acquisition of Bio Blue Bird AG and, with it, the worldwide exclusive rights for Nuvilex to use Austrianova's Cell-in-a-Box(TM) cellulose-based live-cell encapsulation technology for the development of treatments for all types of cancer. Nuvilex has also obtained from Austrianova Singapore the exclusive worldwide rights to use the Cell-in-a-Box(TM) technology for the development of treatments for diabetes.
we also proceeded to purchase the rights to use it for Diabetes...
NEW YORK, NY--(Marketwired - Nov 19, 2013) - Nuvilex, Inc. (OTCQB: NVLX) recently acquired the exclusive worldwide rights to a proprietary cellulose-based live-cell encapsulation technology for developing treatments for all types of cancer, most notably pancreatic cancer. This acquisition should put the company and cell encapsulation-based therapies on the map if its future Phase 3 clinical trials in patients with advanced, inoperable pancreatic cancer produce similar data to that seen in two separate early-phase trials in this disease.
But, Nuvilex didn't stop there. Executives then went out and raised enough capital at a price above the current share price to purchase the same exclusive worldwide rights to the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes. When all is said and done, it is the diabetes acquisition that could make Nuvilex a household name.
bull
Technical....if we trade sideways here with slow moves up it will stabilize the stock and get rid of a lot of the day traders which is a good thing...have patience....the chart and all the indicators look good .....I for one am glad to not see the circus right now....
we are going up just have patience...I am not going anywhere for a long time...I finally found my Hidden Gem
bull
By my charts 0.421 will be the lowest ask....
bull
We don't need those out of the ballpark volumes..a lot of that is just momo's...(momentum day traders) getting alerts and jumping on a stock that is moving up...that is why I don't buy or sell in the first 90 minutes ...amateur hour...they jump on and ride the coaster and dive off..they will play that game all day if they can...that is also why I like power hour (last hour)...they are usually gone by then and I can arrange my portfolio for the future or buy into a new stock I want....this stock will do a lot better when it calms down and moves up in an orderly fashion....I do believe the .30's are gone and we are accumulating here in the .40's...
bull
This is a good place to add if you want more shares...I doubt you will see the .30's again
bull
Key Takeaways
Conclusion: With funding for advanced clinical trials in place, the Nuvilex story has been transformed overnight and prompts a price target increase to $1.05 from $0.75.
The Event: Institutional Funding on Great Terms
Two weeks ago, Nuvilex issued the most important release in company history. Noted institutional investor Lincoln Park invested $2M in NVLX stock and based on the agreement, has committed to invest up to an additional $25M in NVLX stock, at the sole option of the Company. The initial tranche was priced at $0.25, a premium to the previous day’s close. We note that this deal included no warrants or options.
The Great Leverage: Power is in NVLX’s Hands
Clearly, any seasoned investor will quickly recognize that this type of deal and the funder’s reputation illustrate that Nuvilex is no also-ran but a soon-to-be-prime time player in the biotech and medical marijuana arenas. By giving NVLX the sole option for the future investments, NVLX ensures it will be able to fund future, advanced clinical trials. Moreover, the funding will likely be executed in a minimally dilutive series of events. We estimate dilution from a $25M investment to result in 10% dilution or less—a pittance when compared with the leverage NVLX and its investors will get out of the funds.
The Real Story: Milestone Events Galore
Since we began coverage of NVLX 3 years ago, naysayers and short sellers have seemingly controlled the message about the company---and the message was always looking behind rather than ahead. That message minimized the company’s technology, progress and prospects, and thus hurt the valuation. Now that an institution has validated the company, attention will be focused on fundamentals and a series of future milestones and executable events, which means a higher future valuation.
bull
All the longs know NVLX is a bio not a mmj play...that is not even a factor yet...maybe that is why the stock reacted not at all to the mj and hemp stories...and reacted to the funding for PHASE III TRIALS...and as far as food safety, tatoo ink, and cardio health product days....the longs know those days are long gone too...so they are not really a factor for a bio going into the last phase for pancreatic cancer
bull
Emmmci...I have been here...making some portfolio changes today...
I looked at the chart for nvlx and IMO it looks strong ...we traded all day between open and the resistance which was the pivot of 0.46....and we ended up closing right under the pivot...I see that as bullish....I think we go up from here again...
bull
well then my charts are looking bullish